Antibodies with specificity for interleukin 1 (IL 1) were produced in a goat immunized with purified IL 1 alpha obtained from the murine macrophage cell line, P388D1. The anti-IL 1 IgG were capable of completely inhibiting the biologic activity of IL 1 in the murine thymocyte assay but had no effect on IL 2-driven T cell responses. Although the anti-IL 1 IgG were produced by using mouse IL 1, these antibodies also recognized IL 1 prepared from a human monocyte leukemia cell line. An immunoadsorbent column was prepared and used for the large-scale purification of IL 1 in relatively high yield. Approximately 250 micrograms of purified IL 1 were obtained from 50 liters of culture fluid, the yield being 20% of the initial activity. Six major species of IL 1 were resolved by using tris-glycinate discontinuous polyacrylamide gels. The purified IL 1 exhibited 50% of its maximal activity in the thymocyte proliferation assay at a concentration of approximately 1 X 10(-11) M.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
The Protective Effect of IL-17A in Pneumonic Plague Can Be Compensated by Effective Vaccines and Immunization Strategies in Mice.
Vaccines (Basel)
December 2024
Department of Microbiology & Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA.
Plague, caused by , poses a public health threat not only due to sporadic outbreaks across the globe but also due to its potential as a biothreat agent. Ironically, among the seven deadliest pandemics in global history, three were caused by . Pneumonic plague, the more contagious and severe form of the disease, is difficult to contain, requiring either prophylactic antibiotic treatment or vaccination.
View Article and Find Full Text PDFEarly introduction of IL-10 weakens BCG revaccination's protection by suppressing CD4Th1 cell responses.
J Transl Med
December 2024
Department of Pathogen Biology, School of Basic Medicine, Tongji Medical College and State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Hubei Key Laboratory of Drug Target Research and Pharmacodynamic Evaluation, Huazhong University of Science and Technology, Wuhan, China.
Article Synopsis
- The BCG vaccine, the only current vaccine for tuberculosis (TB), shows limited effectiveness in protecting adolescents and adults from active TB, which highlights the need for better understanding of its mechanisms and potential improvements.
- A study conducted on C57BL/6J mice evaluated the effects of BCG vaccination, particularly analyzing cytokine changes, IL-10 expression across various organs, and the immune response following booster doses.
- Results indicated that IL-10 levels increased significantly in the lungs and other organs after revaccination, and blocking IL-10 signaling led to enhanced immune responses, suggesting that targeting IL-10 could improve the vaccine's effectiveness against TB.
Biologics in allergology and clinical immunology: Update on therapies for atopic diseases, urticaria, and angioedema and on safety aspects focusing on hypersensitivity reactions.
Allergol Select
November 2024
Institute of Allergology, Charité Universitätsmedizin Berlin und Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin.
Article Synopsis
- Targeted therapies using biologics for atopic diseases, urticaria, and angioedema are advancing quickly, with several new antibodies developed, tested, and approved for clinical use, like omalizumab and dupilumab.
- There is ongoing research into combining different biologics for enhanced treatment efficacy, expanding their applications to conditions like food allergies and eosinophilic esophagitis.
- There are emerging concerns about unexpected side effects and hypersensitivity reactions associated with these therapies, raising important questions about their safety and mechanisms, particularly in specific patient groups like children.
Article Synopsis
- Hidradenitis suppurativa (HS) is a chronic skin condition marked by inflammation, where cytokines IL-17A and IL-17F are known to be elevated. A monoclonal antibody called bimekizumab targets both IL-17A and IL-17F to treat HS.
- The study utilized RNA sequencing on skin biopsies from HS patients to explore gene expression changes before and after bimekizumab treatment, revealing key genes related to neutrophil activity that are affected by the drug.
- Results showed that dual inhibition of IL-17A and IL-17F more effectively reduced HS-related gene expression and neutrophil movement in cultured cells than targeting either cytok
IL-2 Complexed With Anti-IL-2 Antibody Expands the Maternal T-Regulatory Cell Pool and Alleviates Fetal Loss in Abortion-Prone Mice.
Am J Pathol
November 2024
The Robinson Research Institute and School of Biomedicine, University of Adelaide, Adelaide, South Australia, Australia. Electronic address:
Article Synopsis
- Regulatory T (Treg) cells are crucial for preventing early pregnancy loss, and boosting these cells may improve reproductive success in problematic cases.
- A study using an abortion-prone mouse model showed that administering a specific IL-2 treatment (IL-2/JES6-1) significantly increased the number of beneficial Treg cells in the uterus, leading to improved fetal outcomes.
- Although the treatment reduced the rate of fetal loss from 31% to 10%, it also resulted in a slight decrease in fetal weight during late gestation, indicating potential trade-offs that need further exploration.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!